When was PreludeDx founded?

PreludeDx was founded in 2009 and raised its 1st funding round 3 years after it was founded.

Where is PreludeDx located?

PreludeDx is headquartered in Laguna Hills, United States.

How many employees does PreludeDx have?

As of Jul 31, 2026, the latest employee count at PreludeDx is 93.

Is PreludeDx a funded company?

PreludeDx is a funded company, having raised a total of $51.7M across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 20, 2012.

When was the latest funding round of PreludeDx?

PreludeDx's latest funding was a $***** Series B round on Oct 30, 2025, with participation from 0 investor.

Where does PreludeDx rank among its competitors?

PreludeDx ranks 3rd amongst 102 active competitors, of which 40 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Mammogen, which secured $30M in Jun, 2026.

Who are the top competitors of PreludeDx?

PreludeDx's top competitors include ScreenPoint, Raysearch laboratories and Syantra Health. Among them, Mammogen secured the most recent funding round in June, 2026.

PreludeDx - 2026 Company Profile, Funding & Competitors

PreludeDx is a series B company based in Laguna Hills (United States), founded in 2009. It operates as a Provider of risk assessment test for early stage breast cancer. PreludeDx has raised $51.7M in funding from Evidity Health Capital and GenesisCare. The company has 102 active competitors, including 40 funded and 13 that have exited. Its top competitors include companies like ScreenPoint, Raysearch laboratories and Syantra Health.

Company Details

Provider of risk assessment tests for early-stage breast cancer. The flagship product DCISionRT is targeted at patients who have breast cancer staged at ductal carcinoma in situ (DCIS). The company uses a panel of disease-associated biomarkers and proprietary algorithms to classify DCIS patients into high-risk and low-risk categories. The system has features for predicting the treatment for cancer patients as well.

Website: preludedx.com
Email ID: *****@preludedx.com

Key Metrics

Founded Year

2009

Location

Laguna Hills, United States

Stage

Series B

Total Funding

$51.7M in 8 rounds

Latest Funding Round

Series B, Oct 30, 2025, $*****

Investors

Evidity Health Capital & 3 more

Ranked

3^rd among 102 active competitors

Employee Count

93 as on Jul 31, 2026

Similar Companies

ScreenPoint & 138 more

View PreludeDx's full profile

PreludeDx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Prelude Corporation CIN: 90-0495385 , United States, Active	May 12, 2009	-	33 (As on Dec 31, 2021)	-

PreludeDx has raised a total funding of $51.7M over 8 rounds. Its first funding round was on Sep 20, 2012. PreludeDx has 4 institutional investors.

Here is the list of recent funding rounds of PreludeDx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 30, 2025	8203411	Series B	6847453	9631514	6349681	6450760
Mar 22, 2022	6895936	Series B	9600679	4037373	9940598	2069552
Jul 20, 2021	3969507	Series B	3796352	6550262	GenesisCare	3940787

Access funding benchmarks and valuations. Sign up today!

View details of PreludeDx's funding rounds and investors

PreludeDx's employee count trend

PreludeDx has 93 employees as of Jul 26. Here is PreludeDx's employee count trend over the years:

Uncover PreludeDx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PreludeDx include ScreenPoint, Raysearch laboratories and Syantra Health. Here is the list of Top 10 competitors of PreludeDx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ScreenPoint 2014, Nijmegen (Netherlands), Series C	Developer of artificial intelligence software for analyzing breast imaging mammograms	$47M	Insight Partners, Siemens & 3 others	63/100
2nd	Raysearch laboratories 2000, Stockholm (Sweden), Public	Cloud-based radiation therapy software for oncology professionals	-	Quinary Investment, Corda Campus & 2 others	60/100
3rd	PreludeDx 2009, Laguna Hills (United States), Series B	Provider of risk assessment test for early stage breast cancer	$51.7M	Fjord Ventures, Evidity Health Capital & 2 others	57/100
4th	Syantra Health 2013, Calgary (Canada), Series A	Developer of a blood test device to detect breast cancer	$10.4M	Accelerate Fund, Plug and Play Tech Center ... & 5 others	54/100
5th	Curasight 2013, Copenhagen (Denmark), Series A	Developer of PET ligands for breast cancer indications	$11.5M	PreSeed Ventures	53/100
6th	Mammogen 2020, Aliso Viejo (United States), Series A	Developer of a diagnostic test to detect breast cancer	$32M	-	49/100
7th	Isotropic Imaging 2016, Las Vegas (United States), Public	Innovating breast cancer imaging with dedicated 3D breast CT technology	-	-	48/100
8th	Devicor Medical 1959, Cincinnati (United States), Acquired	Advancing breast care through innovative diagnostic and surgical solutions	$14M	-	48/100
9th	OncoStem 2011, Bengaluru (India), Series A	Developer of prognostic tests for the detection of cancer	$9M	Artiman, Peak XV Partners & 1 others	45/100
10th	Biotheranostics 2008, San Diego (United States), Acquired	Commercial stage molecular diagnostics tests tailored to individual cancer patients.	$32M	MVM, Health Quest Capital & 2 others	44/100